Psychiatric research: psychoproteomics, degradomics and systems biology

References

• Drabik A, Bierczynska-Krzysik A, Bodzon-Kulakowska A, Suder P, Kotlinska J, Silberring J. Proteomics in neurosciences. Mass Spectrom. Rev.26(3), 432–450 (2007).
   PubMedGoogle Scholar
• Kobeissy FH, Warren M, Ottens AK et al. Psychoproteomic analysis of rat cortex following acute methamphetamine exposure. J. Proteome Res. (2008) (In Press).
   PubMedGoogle Scholar
• Nestler EJ. Psychogenomics: opportunities for understanding addiction. J. Neurosci.21(21), 8324–8327 (2001).
   PubMed Web of Science ®Google Scholar
• Choudhary J, Grant SG. Proteomics in postgenomic neuroscience: the end of the beginning. Nat. Neurosci.7(5), 440–445 (2004).
   PubMed Web of Science ®Google Scholar
• Kim SI, Voshol H, van Oostrum J, Hastings TG, Cascio M, Glucksman MJ. Neuroproteomics: expression profiling of the brain’s proteomes in health and disease. Neurochem. Res.29(6), 1317–1331 (2004).
   PubMed Web of Science ®Google Scholar
• Williams K, Wu T, Colangelo C, Nairn AC. Recent advances in neuroproteomics and potential application to studies of drug addiction. Neuropharmacology47(Suppl. 1), 148–166 (2004).
   PubMedGoogle Scholar
• Wang KK, Ottens AK, Liu MC et al. Proteomic identification of biomarkers of traumatic brain injury. Expert Rev. Proteomics2(4), 603–614 (2005).
   PubMed Web of Science ®Google Scholar
• Morrison RS, Kinoshita Y, Johnson MD et al. Proteomic analysis in the neurosciences. Mol. Cell Proteomics1(8), 553–560 (2002).
   PubMedGoogle Scholar
• Wang KK, Ottens A, Haskins W et al. Proteomics studies of traumatic brain injury. Int. Rev. Neurobiol.61, 215–240 (2004).
   PubMed Web of Science ®Google Scholar
• Freeman WM, Brebner K, Amara SG, Reed MS, Pohl J, Phillips AG. Distinct proteomic profiles of amphetamine self-administration transitional states. Pharmacogenomics J.5(3), 203–214 (2005).
   PubMedGoogle Scholar
• Denslow N, Michel ME, Temple MD, Hsu CY, Saatman K, Hayes RL. Application of proteomics technology to the field of neurotrauma. J. Neurotrauma20(5), 401–407 (2003).
   PubMed Web of Science ®Google Scholar
• Missler M, Sudhof TC. Neurexins: three genes and 1001 products. Trends Genet.14(1), 20–26 (1998).
   PubMedGoogle Scholar
• Hunnerkopf R, Grassl J, Thome J. Proteomics: biomarker research in psychiatry. Fortschr. Neurol. Psychiatr.75(10), 579–586 (2007).
   PubMedGoogle Scholar
• Wu Q, Maniatis T. A striking organization of a large family of human neural cadherin-like cell adhesion genes. Cell97(6), 779–790 (1999).
   PubMed Web of Science ®Google Scholar
• Patton WF. Detection technologies in proteome analysis. J. Chromatogr.771(1–2), 3–31 (2002).
   Google Scholar
• Hortin GL, Jortani SA, Ritchie JC Jr, Valdes R Jr, Chan DW. Proteomics: a new diagnostic frontier. Clin. Chem.52(7), 1218–1222 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics1(11), 845–867 (2002).
   PubMed Web of Science ®Google Scholar
• Omenn GS, States DJ, Adamski M et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics5(13), 3226–3245 (2005).
   PubMed Web of Science ®Google Scholar
• Schmidt O, Schulenborg T, Meyer HE, Marcus K, Hamacher M. How proteomics reveals potential biomarkers in brain diseases. Expert Rev. Proteomics2(6), 901–913 (2005).
   PubMed Web of Science ®Google Scholar
• Grant SG, Blackstock WP. Proteomics in neuroscience: from protein to network. J. Neurosci.21(21), 8315–8318 (2001).
   PubMedGoogle Scholar
• Vercauteren FG, Bergeron JJ, Vandesande F, Arckens L, Quirion R. Proteomic approaches in brain research and neuropharmacology. Eur. J. Clin. Pharmacol.500(1–3), 385–398 (2004).
   Google Scholar
• Taylor CM, Pfeiffer SE. Enhanced resolution of glycosylphosphatidylinositol-anchored and transmembrane proteins from the lipid-rich myelin membrane by two-dimensional gel electrophoresis. Proteomics3(7), 1303–1312 (2003).
   PubMed Web of Science ®Google Scholar
• Dackis CA, O’Brien CP. Cocaine dependence: a disease of the brain’s reward centers. J. Subst. Abuse Treat.21(3), 111–117 (2001).
   PubMed Web of Science ®Google Scholar
• Dackis C, O’Brien C. Neurobiology of addiction: treatment and public policy ramifications. Nat. Neurosci.8(11), 1431–1436 (2005).
   PubMed Web of Science ®Google Scholar
• Volkow N, Li TK. The neuroscience of addiction. Nat. Neurosci.8(11), 1429–1430 (2005).
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol. Psychiatry9(6), 557–569 (2004).
   PubMed Web of Science ®Google Scholar
• Volkow N. Drug dependence and addiction, III: expectation and brain function in drug abuse. Am. J. Psychiatry161(4), 621 (2004).
   PubMedGoogle Scholar
• Uhl GR. Molecular genetics of addiction vulnerability. NeuroRx3(3), 295–301 (2006).
   PubMedGoogle Scholar
• Liu QR, Drgon T, Johnson C, Walther D, Hess J, Uhl GR. Addiction molecular genetics: 639,401 SNP whole genome association identifies many “cell adhesion” genes. Am. J. Med. Genet. B Neuropsychiatr. Genet.141(8), 918–925 (2006).
   Google Scholar
• Perrotti LI, Bolanos CA, Choi KH et al. DeltaFosB accumulates in a GABAergic cell population in the posterior tail of the ventral tegmental area after psychostimulant treatment. Eur. J. Neurosci.21(10), 2817–2824 (2005).
   PubMed Web of Science ®Google Scholar
• Bibb JA, Chen J, Taylor JR et al. Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature410(6826), 376–380 (2001).
   PubMed Web of Science ®Google Scholar
• Carlezon WA Jr, Nestler EJ. Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse? Trends Neurosci.25(12), 610–615 (2002).
   PubMed Web of Science ®Google Scholar
• Roche KW. The expanding role of PSD-95: a new link to addiction. Trends Neurosci.27(12), 699–700 (2004).
   PubMedGoogle Scholar
• Nestler EJ. Under siege: the brain on opiates. Neuron16(5), 897–900 (1996).
   PubMed Web of Science ®Google Scholar
• Blackstock WP, Weir MP. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol.17(3), 121–127 (1999).
   PubMed Web of Science ®Google Scholar
• Nestler EJ. Molecular mechanisms of opiate and cocaine addiction. Curr. Opin. Neurobiol.7(5), 713–719 (1997).
   PubMed Web of Science ®Google Scholar
• Tso PH, Wong YH. Molecular basis of opioid dependence: role of signal regulation by G-proteins. Clin. Exp. Pharmacol. Physiol.30(5–6), 307–316 (2003).
   PubMedGoogle Scholar
• Bailey CP, Connor M. Opioids: cellular mechanisms of tolerance and physical dependence. Curr. Opin. Pharmacol.5(1), 60–68 (2005).
   PubMed Web of Science ®Google Scholar
• Ueda H, Inoue M, Mizuno K. New approaches to study the development of morphine tolerance and dependence. Life Sci.74(2–3), 313–320 (2003).
   PubMedGoogle Scholar
• Granados-Soto V, Kalcheva I, Hua X, Newton A, Yaksh TL. Spinal PKC activity and expression: role in tolerance produced by continuous spinal morphine infusion. Pain85(3), 395–404 (2000).
   PubMed Web of Science ®Google Scholar
• Wong CS, Hsu MM, Chou YY, Tao PL, Tung CS. Morphine tolerance increases [3H]MK-801 binding affinity and constitutive neuronal nitric oxide synthase expression in rat spinal cord. Br. J. Anaesth.85(4), 587–591 (2000).
   PubMedGoogle Scholar
• Shui HA, Ho ST, Wang JJ et al. Proteomic analysis of spinal protein expression in rats exposed to repeated intrathecal morphine injection. Proteomics7(5), 796–803 (2007).
   PubMedGoogle Scholar
• Neasta J, Uttenweiler-Joseph S, Chaoui K, Monsarrat B, Meunier JC, Mouledous L. Effect of long-term exposure of SH-SY5Y cells to morphine: a whole cell proteomic analysis. Proteome Sci.4, 23 (2006).
   PubMedGoogle Scholar
• Yang L, Sun ZS, Zhu YP. Proteomic analysis of rat prefrontal cortex in three phases of morphine-induced conditioned place preference. J. Proteome Res.6(6), 2239–2247 (2007).
   PubMed Web of Science ®Google Scholar
• Bodzon-Kulakowska A, Bierczynska-Krzysik A, Drabik A et al. Morphinome – proteome of the nervous system after morphine treatment. Amino acids28(1), 13–19 (2005).
   PubMedGoogle Scholar
• Bierczynska-Krzysik A, Bonar E, Drabik A et al. Rat brain proteome in morphine dependence. Neurochem. Int.49(4), 401–406 (2006).
   PubMedGoogle Scholar
• Li KW, Jimenez CR, van der Schors RC, Hornshaw MP, Schoffelmeer AN, Smit AB. Intermittent administration of morphine alters protein expression in rat nucleus accumbens. Proteomics6(6), 2003–2008 (2006).
   PubMed Web of Science ®Google Scholar
• Moron JA, Abul-Husn NS, Rozenfeld R, Dolios G, Wang R, Devi LA. Morphine administration alters the profile of hippocampal postsynaptic density-associated proteins: a proteomics study focusing on endocytic proteins. Mol. Cell. Proteomics6(1), 29–42 (2007).
   PubMed Web of Science ®Google Scholar
• Li KW. Proteomics of synapse. Anal. Bioanal. Chem.387(1), 25–28 (2007).
   PubMed Web of Science ®Google Scholar
• Prokai L, Zharikova AD, Stevens SM Jr. Effect of chronic morphine exposure on the synaptic plasma-membrane subproteome of rats: a quantitative protein profiling study based on isotope-coded affinity tags and liquid chromatography/mass spectrometry. J. Mass Spectrom.40(2), 169–175 (2005).
   PubMed Web of Science ®Google Scholar
• Warren MW, Kobeissy FH, Liu MC, Hayes RL, Gold MS, Wang KK. Concurrent calpain and caspase-3 mediated proteolysis of a II-spectrin and tau in rat brain after methamphetamine exposure: a similar profile to traumatic brain injury. Life Sci.78(3), 301–309 (2005).
   PubMedGoogle Scholar
• Warren MW, Kobeissy FH, Liu MC, Hayes RL, Gold MS, Wang KK. Ecstasy toxicity: a comparison to methamphetamine and traumatic brain injury. J. Addict. Dis.25(4), 115–123 (2006).
   PubMed Web of Science ®Google Scholar
• Warren MW, Larner SF, Kobeissy FH et al. Calpain and caspase proteolytic markers co-localize with rat cortical neurons after exposure to methamphetamine and MDMA. Acta Neuropathol.114(3), 277–286 (2007).
   PubMed Web of Science ®Google Scholar
• Warren MW, Zheng W, Kobeissy FH et al. Calpain- and caspase-mediated αII-spectrin and tau proteolysis in rat cerebrocortical neuronal cultures after ecstasy or methamphetamine exposure. Int. J. Neuropsychopharmacol.10(4), 479–489 (2007).
   PubMedGoogle Scholar
• Kim SY, Chudapongse N, Lee SM et al. Proteomic analysis of phosphotyrosyl proteins in morphine-dependent rat brains. Brain Res. Mol. Brain Res.133(1), 58–70 (2005).
   PubMedGoogle Scholar
• Kumar A, Choi KH, Renthal W et al. Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron48(2), 303–314 (2005).
   PubMed Web of Science ®Google Scholar
• Levine AA, Guan Z, Barco A, Xu S, Kandel ER, Schwartz JH. CREB-binding protein controls response to cocaine by acetylating histones at the fosB promoter in the mouse striatum. Proc. Natl Acad. Sci. USA102(52), 19186–19191 (2005).
   PubMed Web of Science ®Google Scholar
• Marcus K, Schmidt O, Schaefer H, Hamacher M, van Hall A, Meyer HE. Proteomics – application to the brain. Int. Rev. Neurobiol.61, 285–311 (2004).
   PubMedGoogle Scholar
• Iwazaki T, McGregor IS, Matsumoto I. Protein expression profile in the striatum of acute methamphetamine-treated rats. Brain Res.1097(1), 19–25 (2006).
   PubMed Web of Science ®Google Scholar
• Iwazaki T, McGregor IS, Matsumoto I. Protein expression profile in the striatum of rats with methamphetamine-induced behavioral sensitization. Proteomics7(7), 1131–1139 (2007).
   PubMedGoogle Scholar
• Sokolov BP, Cadet JL. Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness. Neuropsychopharmacology31(5), 956–966 (2006).
   PubMed Web of Science ®Google Scholar
• Ottens AK, Kobeissy FH, Wolper RA et al. A multidimensional differential proteomic platform using dual-phase ion-exchange chromatography-polyacrylamide gel electrophoresis/reversed-phase liquid chromatography tandem mass spectrometry. Anal. Chem.77(15), 4836–4845 (2005).
   PubMedGoogle Scholar
• Svetlov SI, Xiang Y, Oli MW et al. Identification and preliminary validation of novel biomarkers of acute hepatic ischaemia/reperfusion injury using dual-platform proteomic/degradomic approaches. Biomarkers11(4), 355–369 (2006).
   PubMed Web of Science ®Google Scholar
• Kobeissy FH, Ottens AK, Zhang Z et al. Novel differential neuroproteomics analysis of traumatic brain injury in rats. Mol. Cell. Proteomics5(10), 1887–1898 (2006).
   PubMed Web of Science ®Google Scholar
• Lewohl JM, van Dyk DD, Craft GE et al. The application of proteomics to the human alcoholic brain. Ann. NY Acad. Sci.1025, 14–26 (2004).
   PubMedGoogle Scholar
• Kashem MA, James G, Harper C, Wilce P, Matsumoto I. Differential protein expression in the corpus callosum (splenium) of human alcoholics: a proteomics study. Neurochem. Int.50(2), 450–459 (2007).
   PubMedGoogle Scholar
• Pfefferbaum A, Sullivan EV, Mathalon DH, Lim KO. Frontal lobe volume loss observed with magnetic resonance imaging in older chronic alcoholics. Alcohol. Clin. Exp. Res.21(3), 521–529 (1997).
   PubMed Web of Science ®Google Scholar
• Alexander-Kaufman K, Dedova I, Harper C, Matsumoto I. Proteome analysis of the dorsolateral prefrontal region from healthy individuals. Neurochem. Int.51(6–7), 433–439 (2007).
   PubMedGoogle Scholar
• Alexander-Kaufman K, Harper C, Wilce P, Matsumoto I. Cerebellar vermis proteome of chronic alcoholic individuals. Alcohol. Clin. Exp. Res.31(8), 1286–1296 (2007).
   PubMedGoogle Scholar
• Alexander-Kaufman K, James G, Sheedy D, Harper C, Matsumoto I. Differential protein expression in the prefrontal white matter of human alcoholics: a proteomics study. Mol. Psychiatry11(1), 56–65 (2006).
   PubMedGoogle Scholar
• Matsuda-Matsumoto H, Iwazaki T, Kashem MA, Harper C, Matsumoto I. Differential protein expression profiles in the hippocampus of human alcoholics. Neurochem. Int.51(6–7), 370–376 (2007).
   PubMedGoogle Scholar
• Matsumoto I, Alexander-Kaufman K, Iwazaki T, Kashem MA, Matsuda-Matsumoto H. CNS proteomes in alcohol and drug abuse and dependence. Expert Rev. Proteomics4(4), 539–552 (2007).
   PubMed Web of Science ®Google Scholar
• Quinn HR, Matsumoto I, Callaghan PD et al. Adolescent rats find repeated δ(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology33(5), 1113–1126 (2008).
   PubMed Web of Science ®Google Scholar
• Johnston-Wilson NL, Sims CD, Hofmann JP et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol. Psychiatry5(2), 142–149 (2000).
   PubMed Web of Science ®Google Scholar
• Susser E, Wanderling J. Epidemiology of nonaffective acute remitting psychosis vs schizophrenia. Sex and sociocultural setting. Arch. Gen. Psychiatry51(4), 294–301 (1994).
   PubMed Web of Science ®Google Scholar
• Lakhan SE. Schizophrenia proteomics: biomarkers on the path to laboratory medicine? Diagn. Pathol.1, 11 (2006).
   PubMed Web of Science ®Google Scholar
• Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science296(5568), 692–695 (2002).
   PubMed Web of Science ®Google Scholar
• Frankle WG, Lerma J, Laruelle M. The synaptic hypothesis of schizophrenia. Neuron39(2), 205–216 (2003).
   PubMedGoogle Scholar
• Benes FM. Emerging principles of altered neural circuitry in schizophrenia. Brain Res.31(2–3), 251–269 (2000).
   Google Scholar
• Cotter D, Landau S, Beasley C et al. The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol. Psychiatry51(5), 377–386 (2002).
   PubMed Web of Science ®Google Scholar
• Gallinat J, Obermayer K, Heinz A. Systems neurobiology of the dysfunctional brain: schizophrenia. Pharmacopsychiatry40(Suppl. 1), S40–S44 (2007).
   Google Scholar
• Iritani S. Neuropathology of schizophrenia: a mini review. Neuropathology27(6), 604–608 (2007).
   PubMedGoogle Scholar
• Tan HY, Callicott JH, Weinberger DR. Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb. Cortex17(Suppl. 1), i171–i181 (2007).
   PubMed Web of Science ®Google Scholar
• Waddington JL. Neuroimaging and other neurobiological indices in schizophrenia: relationship to measurement of functional outcome. Br. J. Psychiatry Suppl.50, S52–S57 (2007).
   PubMedGoogle Scholar
• Waddington JL, Corvin AP, Donohoe G, O’Tuathaigh CM, Mitchell KJ, Gill M. Functional genomics and schizophrenia: endophenotypes and mutant models. Psychiatr. Clin. North Am.30(3), 365–399 (2007).
   PubMed Web of Science ®Google Scholar
• Clark WG. Schizophrenia and genomics: linking research to practice. J. Psychosoc. Nurs. Ment. Health Serv.45(6), 24–28 (2007).
   PubMedGoogle Scholar
• McClellan JM, Susser E, King MC. Schizophrenia: a common disease caused by multiple rare alleles. Br. J. Psychiatry190, 194–199 (2007).
   PubMedGoogle Scholar
• Vazza G, Bertolin C, Scudellaro E et al. Genome-wide scan supports the existence of a susceptibility locus for schizophrenia and bipolar disorder on chromosome 15q26. Mol. Psychiatry12(1), 87–93 (2007).
   PubMed Web of Science ®Google Scholar
• Owen MJ. Genomic approaches to schizophrenia. Clin. Ther.27(Suppl. A), S2–S7 (2005).
   PubMedGoogle Scholar
• Hallmayer JF, Kalaydjieva L, Badcock J et al. Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficit. Am. J. Hum. Genet.77(3), 468–476 (2005).
   PubMed Web of Science ®Google Scholar
• Porteous DJ, Evans KL, Millar JK et al. Genetics of schizophrenia and bipolar affective disorder: strategies to identify candidate genes. Cold Spring Harb. Symp. Quant. Biol.68, 383–394 (2003).
   PubMedGoogle Scholar
• Prabakaran S, Swatton JE, Ryan MM et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry9(7), 684–697, 643 (2004).
   PubMed Web of Science ®Google Scholar
• Edgar PF, Schonberger SJ, Dean B, Faull RL, Kydd R, Cooper GJ. A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer’s disease individuals. Mol. Psychiatry4(2), 173–178 (1999).
   PubMedGoogle Scholar
• van Kammen DP, Guidotti A, Kelley ME et al. CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships. Biol. Psychiatry34(8), 515–522 (1993).
   PubMedGoogle Scholar
• Jiang L, Lindpaintner K, Li HF et al. Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia. Amino Acids25(1), 49–57 (2003).
   PubMed Web of Science ®Google Scholar
• Huang JT, McKenna T, Hughes C, Leweke FM, Schwarz E, Bahn S. CSF biomarker discovery using label-free nano-LC-MS based proteomic profiling: technical aspects. J. Sep. Sci.30(2), 214–225 (2007).
   PubMed Web of Science ®Google Scholar
• Clark D, Dedova I, Cordwell S, Matsumoto I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol. Psychiatry11(5), 459–470, 423 (2006).
   PubMedGoogle Scholar
• Clark D, Dedova I, Cordwell S, Matsumoto I. Altered proteins of the anterior cingulate cortex white matter proteome in schizophrenia. Proteomics Clin. Appl.1(2), 157–166 (2007).
   PubMed Web of Science ®Google Scholar
• Hempel A, Hempel E, Schonknecht P, Stippich C, Schroder J. Impairment in basal limbic function in schizophrenia during affect recognition. Psychiatr. Res. Neuroim.122(2), 115–124 (2003).
   PubMed Web of Science ®Google Scholar
• Carter CS, Barch DB, McDonald A et al. Anterior cingulate cortex and cognitive disability in schizophrenia. Biol. Psychiatry45(8S), S60–S60 (1999).
   Google Scholar
• Ross LL, Barch DB, Cohen JD et al. Anterior cingulate cortex dysfunction and cognitive disability in schizophrenia.J. Cogn. Neurosci.62–63 (1999).
   Google Scholar
• Salgado-Pineda P, Baeza I, Perez-Gomez M et al. Sustained attention impairment correlates to gray matter decreases in first episode neuroleptic-naive schizophrenic patients. Neuroimage19(2), 365–375 (2003).
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Hirao K, Namiki C et al. Anterior cingulate pathology and social cognition in schizophrenia: a study of gray matter, white matter and sulcal morphometry. Neuroimage36(4), 1236–1245 (2007).
   PubMed Web of Science ®Google Scholar
• Zetzsche T, Preuss U, Frodl T et al. In-vivo topography of structural alterations of the anterior cingulate in patients with schizophrenia: new findings and comparison with the literature. Schizophr. Res.96(1–3), 34–45 (2007).
   PubMedGoogle Scholar
• Mitelman SA, Brickman AM, Shihabuddin L et al. A comprehensive assessment of gray and white matter volumes and their relationship to outcome and severity in schizophrenia. Neuroimage37(2), 449–462 (2007).
   PubMed Web of Science ®Google Scholar
• Sivagnanasundaram S, Crossett B, Dedova I, Cordwell S, Matsumoto I. Abnormal pathways in the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study. Proteomics Clin. Appl.1(10), 1291–1305 (2007).
   PubMed Web of Science ®Google Scholar
• Mu J, Xie P, Yang ZS et al. Neurogenesis and major depression: implications from proteomic analyses of hippocampal proteins in a rat depression model. Neurosci. Lett.416(3), 252–256 (2007).
   PubMedGoogle Scholar
• Belmaker RH, Agam G. Major depressive disorder. N. Engl. J. Med.358(1), 55–68 (2008).
   PubMed Web of Science ®Google Scholar
• Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res. Rev.4(2), 141–194 (2005).
   PubMed Web of Science ®Google Scholar
• Merali Z, Du L, Hrdina P et al. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABAA receptor subunits in frontal cortical brain region. J. Neurosci.24(6), 1478–1485 (2004).
   PubMed Web of Science ®Google Scholar
• Naismith SL, Hickie IB, Turner K et al. Neuropsychological performance in patients with depression is associated with clinical, etiological and genetic risk factors. J. Clin. Exp. Neuropsychol.25(6), 866–877 (2003).
   PubMed Web of Science ®Google Scholar
• Campbell S, Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J. Psychiatry Neurosci.29(6), 417–426 (2004).
   PubMed Web of Science ®Google Scholar
• Huchzermeyer C, Albus K, Gabriel HJ et al. g oscillations and spontaneous network activity in the hippocampus are highly sensitive to decreases in pO2 and concomitant changes in mitochondrial redox state. J. Neurosci.28(5), 1153–1162 (2008).
   PubMedGoogle Scholar
• Zhao Y, Ma R, Shen J, Su H, Xing D, Du L. A mouse model of depression induced by repeated corticosterone injections. Eur. J. Clin. Pharmacol.581(1,2), 113–120 (2007).
   Google Scholar
• Bergstrom A, Jayatissa MN, Mork A, Wiborg O. Stress sensitivity and resilience in the chronic mild stress rat model of depression; an in situ hybridization study. Brain Res.1196, 41–52 (2007).
   PubMedGoogle Scholar
• Santarelli L, Saxe M, Gross C et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science301(5634), 805–809 (2003).
   PubMed Web of Science ®Google Scholar
• Duman RS, Malberg J, Nakagawa S, D’Sa C. Neuronal plasticity and survival in mood disorders. Biol. Psychiatry48(8), 732–739 (2000).
   PubMed Web of Science ®Google Scholar
• Khawaja X, Xu J, Liang JJ, Barrett JE. Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: Implications for depressive disorders and future therapies. J. Neurosci. Res.75(4), 451–460 (2004).
   PubMedGoogle Scholar
• Ali SF, Chang LW, Slikker W Jr. Biogenic amines as biomarkers for neurotoxicity. Biomed. Environ. Sci.4(1–2), 207–216 (1991).
   PubMedGoogle Scholar
• Ishigami A, Tokunaga I, Gotohda T, Kubo S. Immunohistochemical study of myoglobin and oxidative injury-related markers in the kidney of methamphetamine abusers. Leg. Med. (Tokyo)5(1), 42–48 (2003).
   PubMedGoogle Scholar
• Yuan X, Desiderio DM. Human cerebrospinal fluid peptidomics. J. Mass Spectrom.40(2), 176–181 (2005).
   PubMed Web of Science ®Google Scholar
• Yuan X, Desiderio DM. Proteomics analysis of human cerebrospinal fluid. J. Chromatogr.815(1–2), 179–189 (2005).
   Google Scholar
• Yuan X, Desiderio DM. Proteomics analysis of prefractionated human lumbar cerebrospinal fluid. Proteomics5(2), 541–550 (2005).
   PubMed Web of Science ®Google Scholar
• Davidsson P, Sjogren M. The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis. Markers21(2), 81–92 (2005).
   PubMed Web of Science ®Google Scholar
• Huang JT, Leweke FM, Tsang TM et al. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS ONE2(1), E756 (2007).
   PubMed Web of Science ®Google Scholar
• Bendikov I, Nadri C, Amar S et al. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr. Res.90(1–3), 41–51 (2007).
   PubMed Web of Science ®Google Scholar
• Chua SE, Cheung C, Cheung V et al. Cerebral grey, white matter and CSF in never-medicated, first-episode schizophrenia. Schizophr. Res.89(1–3), 12–21 (2007).
   PubMed Web of Science ®Google Scholar
• Muller N, Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox. Res.10(2), 131–148 (2006).
   PubMed Web of Science ®Google Scholar
• Raedler TJ, Wiedemann K. CSF-studies in neuropsychiatric disorders. Neuro Endocrinol. Lett.27(3), 297–305 (2006).
   PubMed Web of Science ®Google Scholar
• Frye MA, Tsai GE, Huggins T, Coyle JT, Post RM. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol. Psychiatry61(2), 162–166 (2007).
   PubMed Web of Science ®Google Scholar
• Haskins WE, Kobeissy FH, Wolper RA et al. Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry. J. Neurotrauma22(6), 629–644 (2005).
   PubMed Web of Science ®Google Scholar
• Motoyama A, Xu T, Ruse CI, Wohlschlegel JA, Yates JR III. Anion and cation mixed-bed ion exchange for enhanced multidimensional separations of peptides and phosphopeptides. Anal. Chem.79(10), 3623–3634 (2007).
   PubMed Web of Science ®Google Scholar
• Delahunty CM, Yates JR III. MudPIT: multidimensional protein identification technology. BioTechniques43(5), 563, 565, 567 passim (2007).
   PubMed Web of Science ®Google Scholar
• Abdi F, Quinn JF, Jankovic J et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis.9(3), 293–348 (2006).
   PubMed Web of Science ®Google Scholar
• Melanson JE, Avery SL, Pinto DM. High-coverage quantitative proteomics using amine-specific isotopic labeling. Proteomics6(16), 4466–4474 (2006).
   PubMedGoogle Scholar
• Sato T, Ishihama Y, Oda Y. Quantitative proteomics of mouse brain and specific protein-interaction studies using stable isotope labeling. Methods Mol. Biol.359, 53–70 (2007).
   PubMedGoogle Scholar
• Nilsson CL, Larsson T, Gustafsson E, Karlsson KA, Davidsson P. Identification of protein vaccine candidates from Helicobacter pylori using a preparative two-dimensional electrophoretic procedure and mass spectrometry. Anal. Chem.72(9), 2148–2153 (2000).
   PubMed Web of Science ®Google Scholar
• Davidsson P, Folkesson S, Christiansson M et al. Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun. Mass Spectrom.16(22), 2083–2088 (2002).
   PubMed Web of Science ®Google Scholar
• Zhan X, Desiderio DM. Nitroproteins from a human pituitary adenoma tissue discovered with a nitrotyrosine affinity column and tandem mass spectrometry. Anal. Biochem.354(2), 279–289 (2006).
   PubMed Web of Science ®Google Scholar
• Gokulrangan G, Zaidi A, Michaelis ML, Schoneich C. Proteomic analysis of protein nitration in rat cerebellum: effect of biological aging. J. Neurochem.100(6), 1494–1504 (2007).
   PubMedGoogle Scholar
• Vaishnav RA, Getchell ML, Poon HF et al. Oxidative stress in the aging murine olfactory bulb: redox proteomics and cellular localization. J. Neurosci. Res.85(2), 373–385 (2007).
   PubMedGoogle Scholar
• Sultana R, Perluigi M, Butterfield DA. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer’s disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid. Redox Signal.8(11–12), 2021–2037 (2006).
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Perluigi M, Sultana R. Oxidative stress in Alzheimer’s disease brain: new insights from redox proteomics. Eur. J. Clin. Pharmacol.545(1), 39–50 (2006).
   Google Scholar
• Poon HF, Shepherd HM, Reed TT et al. Proteomics analysis provides insight into caloric restriction mediated oxidation and expression of brain proteins associated with age-related impaired cellular processes: mitochondrial dysfunction, glutamate dysregulation and impaired protein synthesis. Neurobiol. Aging27(7), 1020–1034 (2006).
   PubMed Web of Science ®Google Scholar
• Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer’s disease brain. J. Neurochem.85(6), 1394–1401 (2003).
   PubMed Web of Science ®Google Scholar
• Do KQ, Trabesinger AH, Kirsten-Kruger M et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci.12(10), 3721–3728 (2000).
   PubMed Web of Science ®Google Scholar
• Taneli F, Pirildar S, Akdeniz F, Uyanik BS, Ari Z. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch. Med. Res.35(5), 401–405 (2004).
   PubMed Web of Science ®Google Scholar
• Ramirez J, Garnica R, Boll MC, Montes S, Rios C. Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study. Schizophr. Res.68(2–3), 357–361 (2004).
   PubMed Web of Science ®Google Scholar
• Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 1–26 PMID: 18205981 (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science289(5482), 1202–1206 (2000).
   PubMed Web of Science ®Google Scholar
• Lopez-Otin C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol.3(7), 509–519 (2002).
   PubMed Web of Science ®Google Scholar
• auf dem Keller U, Doucet A, Overall CM. Protease research in the era of systems biology. Biol. Chem.388(11), 1159–1162 (2007).
   PubMed Web of Science ®Google Scholar
• Warren MW, Zheng W, Kobeissy FH et al. Calpain- and caspase-mediated αII-spectrin and tau proteolysis in rat cerebrocortical neuronal cultures after ecstasy or methamphetamine exposure. Int. J. Neuropsychopharmacol.10(4), 479–489 (2007).
   PubMedGoogle Scholar
• Bernath E, Kupina N, Liu MC, Hayes RL, Meegan C, Wang KK. Elevation of cytoskeletal protein breakdown in aged Wistar rat brain. Neurobiol. Aging27(4), 624–632 (2006).
   PubMedGoogle Scholar
• Lee AY, Park BC, Jang M et al. Identification of caspase-3 degradome by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization-time of flight analysis. Proteomics4(11), 3429–3436 (2004).
   PubMedGoogle Scholar
• Overall CM, Dean RA. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev.25(1), 69–75 (2006).
   PubMed Web of Science ®Google Scholar
• Liu MC, Akle V, Zheng W et al. Comparing calpain- and caspase-3-mediated degradation patterns in traumatic brain injury by differential proteome analysis. Biochem. J.394(Pt 3), 715–725 (2006).
   PubMedGoogle Scholar
• Dunckley T, Coon KD, Stephan DA. Discovery and development of biomarkers of neurological disease. Drug Discov. Today10(5), 326–334 (2005).
   PubMed Web of Science ®Google Scholar
• Hollywood K, Brison DR, Goodacre R. Metabolomics: current technologies and future trends. Proteomics6(17), 4716–4723 (2006).
   PubMed Web of Science ®Google Scholar
• Ohdoi C, Nyhan WL, Kuhara T. Chemical diagnosis of Lesch–Nyhan syndrome using gas chromatography-mass spectrometry detection. J. Chromatogr. B792(1), 123–130 (2003).
   PubMedGoogle Scholar
• Kell DB. Metabolomics and systems biology: making sense of the soup. Curr. Opin. Microbiol.7(3), 296–307 (2004).
   PubMed Web of Science ®Google Scholar
• Westerhoff HV, Palsson BO. The evolution of molecular biology into systems biology. Nat. Biotechnol.22(10), 1249–1252 (2004).
   PubMed Web of Science ®Google Scholar
• Noble F, Roques BP. Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs. Expert Opin. Ther. Targets11(2), 145–159 (2007).
   PubMed Web of Science ®Google Scholar
• Terenius L, Sandin J, Sakurada T. Nociceptin/orphanin FQ metabolism and bioactive metabolites. Peptides21(7), 919–922 (2000).
   PubMedGoogle Scholar
• Chen H, Noble F, Coric P, Fournie-Zaluski MC, Roques BP. Aminophosphinic inhibitors as transition state analogues of enkephalin-degrading enzymes: a class of central analgesics. Proc. Natl Acad. Sci. USA95(20), 12028–12033 (1998).
   PubMedGoogle Scholar
• Chen H, Noble F, Mothe A et al. Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities. J. Med. Chem.43(7), 1398–1408 (2000).
   PubMed Web of Science ®Google Scholar
• Warren M, Larner S, Jeung J et al. Calpain and caspase proteolytic markers co-localize with rat cortical neurons after meth and MDMA use. J. Neurochem.114(3), 277–286 (2007).
   Google Scholar
• Wallace TL, Vorhees CV, Zemlan FP, Gudelsky GA. Methamphetamine enhances the cleavage of the cytoskeletal protein tau in the rat brain. Neuroscience116(4), 1063–1068 (2003).
   PubMedGoogle Scholar
• Skynner HA, Amos DP, Murray F et al. Proteomic analysis identifies alterations in cellular morphology and cell death pathways in mouse brain after chronic corticosterone treatment. Brain Res.1102(1), 12–26 (2006).
   PubMedGoogle Scholar
• Kitano H. Computational systems biology. Nature420(6912), 206–210 (2002).
   PubMed Web of Science ®Google Scholar
• Kitano H. Systems biology: a brief overview. Science295(5560), 1662–1664 (2002).
   PubMed Web of Science ®Google Scholar
• Barabasi AL, Albert R. Emergence of scaling in random networks. Science286(5439), 509–512 (1999).
   PubMed Web of Science ®Google Scholar
• Grant SG. Systems biology in neuroscience: bridging genes to cognition. Curr. Opin. Neurobiol.13(5), 577–582 (2003).
   PubMedGoogle Scholar
• Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature422(6928), 198–207 (2003).
   PubMed Web of Science ®Google Scholar
• Dujon B, Albermann K, Aldea M et al. The nucleotide sequence of Saccharomyces cerevisiae chromosome XV. Nature387(6632 Suppl.), 98–102 (1997).
   PubMedGoogle Scholar
• Johnston M, Hillier L, Riles L et al. The nucleotide sequence of Saccharomyces cerevisiae chromosome XII. Nature387(6632 Suppl.), 87–90 (1997).
   PubMed Web of Science ®Google Scholar
• Bussey H, Storms RK, Ahmed A et al. The nucleotide sequence of Saccharomyces cerevisiae chromosome XVI. Nature387(6632 Suppl.), 103–105 (1997).
   PubMed Web of Science ®Google Scholar
• Ideker T, Thorsson V, Ranish JA et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science292(5518), 929–934 (2001).
   PubMed Web of Science ®Google Scholar
• van der Greef J, Stroobant P, van der Heijden R. The role of analytical sciences in medical systems biology. Curr. Opin. Chem. Biol.8(5), 559–565 (2004).
   PubMed Web of Science ®Google Scholar
• van der Greef J. Systems biology, connectivity and the future of medicine. Syst. Biol. (Stevenage)152(4), 174–178 (2005).
   PubMedGoogle Scholar
• Jordan BA, Ziff EB. Getting to synaptic complexes through systems biology. Genome Biol.7(4), 214 (2006).
   PubMedGoogle Scholar
• Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol.2(9), 458–466 (2006).
   PubMed Web of Science ®Google Scholar
• Ikonomidou C, Mosinger JL, Salles KS, Labruyere J, Olney JW. Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-aspartate neurotoxicity. J. Neurosci.9(8), 2809–2818 (1989).
   PubMed Web of Science ®Google Scholar
• Wang C, Showalter VM, Hillman GR, Johnson KM. Chronic phencyclidine increases NMDA receptor NR1 subunit mRNA in rat forebrain. J. Neurosci. Res.55(6), 762–769 (1999).
   PubMedGoogle Scholar
• Ikonomidou C, Bosch F, Miksa M et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science283(5398), 70–74 (1999).
   PubMed Web of Science ®Google Scholar
• Abi-Saab WM, D’Souza DC, Moghaddam B, Krystal JH. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry31(Suppl. 2), 104–109 (1998).
   PubMed Web of Science ®Google Scholar
• Carter AJ. Antagonists of the NMDA receptor-channel complex and motor coordination. Life Sci.57(10), 917–929 (1995).
   PubMedGoogle Scholar
• Catts SV, Ward PB, Lloyd A et al. Molecular biological investigations into the role of the NMDA receptor in the pathophysiology of schizophrenia. Aust. NZ J. Psychiatry31(1), 17–26 (1997).
   PubMed Web of Science ®Google Scholar
• Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch. Gen. Psychiatry48(11), 996–1001 (1991).
   PubMed Web of Science ®Google Scholar
• Slikker W Jr, Paule MG, Wright LK, Patterson TA, Wang C. Systems biology approaches for toxicology. J. Appl. Toxicol.27(3), 201–217 (2007).
   PubMedGoogle Scholar
• Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (Copenh.)20, 140–144 (1963).
   PubMedGoogle Scholar
• Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience41(1), 1–24 (1991).
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Rodenhiser J, Printz D et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl Acad. Sci. USA97(14), 8104–8109 (2000).
   PubMed Web of Science ®Google Scholar
• Juckel G, Schlagenhauf F, Koslowski M et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage29(2), 409–416 (2006).
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry46(1), 56–72 (1999).
   PubMed Web of Science ®Google Scholar
• Krystal JH, Perry EB Jr, Gueorguieva R et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch. Gen. Psychiatry62(9), 985–994 (2005).
   PubMed Web of Science ®Google Scholar
• Jentsch JD, Taylor JR, Roth RH. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology19(2), 105–113 (1998).
   PubMed Web of Science ®Google Scholar
• Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry39(Suppl. 1), S10–S14 (2006).
   PubMed Web of Science ®Google Scholar
• Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin. Neurosci.8(1), 137–142 (2006).
   PubMedGoogle Scholar
• Sesack SR, Carr DB, Omelchenko N, Pinto A. Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann. NY Acad. Sci.1003, 36–52 (2003).
   PubMedGoogle Scholar
• Mann M. Functional and quantitative proteomics using SILAC. Nat. Rev. Mol. Cell Biol.7(12), 952–958 (2006).
   PubMed Web of Science ®Google Scholar